HELPER研究:恩度持续静脉输注联合依托泊苷+顺铂同步放疗治疗不可切除III期非小细胞肺癌的II期试验
该前瞻性II期研究评估恩度(抗血管生成剂)持续静脉输注联合依托泊苷+顺铂同步放疗治疗不可切除III期非小细胞肺癌的疗效与毒性。2012年11月至2015年6月入组73例、可评估67例,中位无进展生存期13.3个月、中位总生存期34.7个月,≥3级不良事件发生率58.2%。结论认为该方案未延长中位无进展生存期,但总生存期较优、2年无进展生存期有前景且毒性可耐受。
要点
- 可评估67例中位无进展生存期13.3个月、中位总生存期34.7个月,2年无进展生存率34.8%、总生存率59.9%。
- ≥3级不良事件发生率58.2%,最常见为白细胞减少(44.8%)。
- 作者结论:该方案未延长中位无进展生存期,但总生存期较优、2年无进展生存期有前景且毒性可耐受。
核心结论
- 对于不可切除III期非小细胞肺癌,恩度持续静脉输注联合依托泊苷+顺铂同步放疗未延长中位无进展生存期,但获得较优的总生存期和有前景的2年无进展生存期,毒性可耐受。
研究设计与样本
- 前瞻性II期研究,入组未经治疗、病理确诊的不可切除III期非小细胞肺癌患者。
- 2012年11月至2015年6月共入组73例,可评估67例,中位年龄59岁,66%为鳞状细胞癌。
- 放疗剂量60-66 Gy,恩度7.5 mg/m2/24 h持续120小时、每周期14天,共4周期;依托泊苷50 mg/m2第1-5天+顺铂50 mg/m2第1、8天,每周期28天,共2周期。
- 主要终点为无进展生存期,次要终点包括缓解率、总生存期、局部区域无复发生存期、无远处转移生存期和不良事件。
主要发现
- ≥3级不良事件发生率为58.2%,最常见的≥3级不良事件为白细胞减少(44.8%)。
- 缓解率为76.1%。
- 中位无进展生存期13.3个月,中位总生存期34.7个月。
- 2年无进展生存率34.8%、总生存率59.9%、局部区域无复发生存率54.7%、无远处转移生存率68.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The prognosis of unresectable stage III non-small cell lung cancer (NSCLC) was poor even after concurrent chemoradiotherapy. There remains a great need to develop novel therapeutic agents in combination with CCRT to improve outcomes. This prospective study sought to evaluate the efficacy and toxicities of the addition of endostar, an anti-angiogenesis agent, to concurrent etoposide, cisplatin (EP) and radiotherapy for treatment of patients with NSCLC. PATIENTS AND METHODS: Patients with untreated pathologically confirmed inoperable stage III NSCLC were eligible. Radiation at doses of 60-66 Gy, four cycles of endostar (7.5 mg/m2/24 h × 120 h, 14 days/cycle), and two cycles of EP (etoposide 50 mg/m2 on days 1-5 and cisplatin 50 mg/m2 on days 1 and 8, 28 days/cycle) were delivered. The primary endpoint was progression-free survival (PFS). The secondary endpoints were response rate and overall survival (OS), locoregional relapse-free survival (LRFS) distant metastasis-free survival (DMFS) and adverse events (AE). RESULTS: From November 2012 to June 2015, 73 patients were enrolled, and 67 patients were evaluable. The median age was 59 years. Sixty-six percent of the patients had squamous cell carcinoma. Grade ≥3 AEs occurred in 58.2% of the patients. The most common Grade ≥3 AE was leucopenia (44.8%). The response rate was 76.1%. The median times of PFS and OS were 13.3 months and 34.7 months, respectively. The 2-year PFS, OS, LRFS and DMFS rates were 34.8%, 59.9%, 54.7% and 68.5%, respectively. CONCLUSIONS: For patients with unresectable stage III NSCLC, continuous intravenous endostar in combination with concurrent EP and radiotherapy did not prolong median PFS, although it got preferable OS, promising 2-year PFS with tolerable toxicities.
引用
- Zhai Y, Ma H, Hui Z, et al. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer. Radiother Oncol. 2018. PMID: 30773184. doi:10.1016/j.radonc.2018.10.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。